scholarly journals Positive urinary fluorescence in situ hybridization indicates poor prognosis in patients with upper tract urothelial carcinoma

Oncotarget ◽  
2018 ◽  
Vol 9 (18) ◽  
pp. 14652-14660 ◽  
Author(s):  
Bao Guan ◽  
Yicong Du ◽  
Xiaohong Su ◽  
Zhenpeng Cao ◽  
Yifan Li ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Urothelial Carcinoma ◽  
Poor Prognosis ◽  
Upper Tract Urothelial Carcinoma ◽  
Upper Tract

The Impact of Fluorescence in situ Hybridization on the Staging of Upper Tract Urothelial Carcinoma

2021 ◽  
pp. 1-6
Author(s):  
Lennert Eismann ◽  
Jan-Niclas Mumm ◽  
Lucas Bohn ◽  
Christian Wülfing ◽  
Ruth Knüchel-Clarke ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Urothelial Carcinoma ◽  
Upper Tract Urothelial Carcinoma ◽  
Final Histology ◽  
T Stage ◽  
Fish Group ◽  
Fish Cohort ◽  
The Impact

<b><i>Objectives:</i></b> The aim of the study was to evaluate the impact of fluorescence in situ hybridization (FISH) diagnostics on the T stage in final histology specimen of patients undergoing radical nephroureterectomy (RNU) due to upper tract urothelial carcinoma (UTUC) at a large tertiary care center. <b><i>Methods:</i></b> We retrospectively analyzed patients who underwent RNU at our center between 2008 and 2020. Inclusion criteria were RNU due to UTUC. Urine cytologies were used for FISH analysis to detect chromosomal abnormalities. Pre-FISH group was defined as patients without access to routine preoperative urinary FISH testing (2008–2014), and FISH group was defined as patients with access to routine FISH testing. Primary outcome was T stage in final histology. Statistical analysis was performed by χ<sup>2</sup> test and Mann-Whitney <i>U</i> test. <b><i>Results:</i></b> Out of 212 patients who underwent RNU at our center between 2008 and 2020, 155 patients were included into the final analysis. The median age was 71 (range 33–90) years, and 108 (69.7%) patients were male and 47 (30.3%) female. Age and gender were not differently distributed in both groups (age: <i>p</i> = 0.925; gender: <i>p</i> = 0.682). Organ-confined disease was found in 37/72 patients in the pre-FISH cohort and in 48/83 patients in the FISH cohort (<i>p</i> = 0.422). Within organ-confined disease, 18/37 patients revealed a T stage smaller than T1 in the pre-FISH cohort and 35/48 patients in the FISH cohort (<i>p</i> = 0.022). <b><i>Conclusions:</i></b> Preoperative FISH diagnostics add important information to preoperative diagnostic workup of patients with UTUC. Within organ-confined disease, a significant shift toward T stages lower than T1 is observed. Further research is required to determine the impact of this shift on survival in UTUC.

Improved Filter Method for Urine Sediment Detection of Urothelial Carcinoma by Fluorescence In Situ Hybridization

2007 ◽  
Vol 131 (10) ◽  
pp. 1574-1577 ◽  
Author(s):  
Isabelle Meiers ◽  
Harpreet Singh ◽  
Deloar Hossain ◽  
Kevin Lang ◽  
Lina Liu ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Urothelial Carcinoma ◽  
Urine Cytology ◽  
Filter Method ◽  
Urine Sediment ◽  
Specific Test ◽  
Significant Difference ◽  
Time Required

AbstractContext.—Fluorescence in situ hybridization (FISH) of voided urine sediment is a sensitive and specific test for the detection of urothelial carcinoma. The time required for slide preparation using the conventional cytospin method is lengthy.Objective.—To present an alternative to the conventional cytospin method.Design.—We compared the results of an improved filter monolayer method with published results of the conventional cytospin method. A total of 624 patients with cytology and FISH analyses were followed with cystoscopy and/ or bladder biopsy. Fluorescence in situ hybridization analysis was performed on 624 cases using fluorescence-labeled probes to the pericentromeric regions of chromosomes 3, 7, and 17 and band 9p21; cytology was also performed in all cases.Results.—A total of 217 (34.7%) of 624 patients had follow-up bladder biopsies, and 170 of these (78.3%) had urothelial carcinoma. The sensitivity for cancer detection was higher for FISH than for urine cytology (92.9% [158/ 170] for FISH vs 72.9% [124/170] for urine cytology, P = &lt;5%). The specificity was equivalent for FISH and urine cytology (97.5% [443/454] for FISH vs 92.2% [419/454] for cytology). The sensitivity for FISH was better (92.9% vs 81%), and there was no significant difference in specificity (97.5% vs 96%) between the filter method and the conventional cytospin method. Unlike the conventional cytospin method, the filter method did not require multiple centrifugation and decantation steps or investment in dedicated equipment.Conclusions.—The improved filter method was faster, easier, and less expensive than published results with the conventional cytospin method with better sensitivity and equivalent specificity.

scholarly journals Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Blood ◽  
2006 ◽  
Vol 108 (5) ◽  
pp. 1724-1732 ◽  
Author(s):  
Ichiro Hanamura ◽  
James P. Stewart ◽  
Yongsheng Huang ◽  
Fenghuang Zhan ◽  
Madhumita Santra ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Disease Progression ◽  
Monoclonal Gammopathy ◽  
Poor Prognosis ◽  
Chromosome Band ◽  
Newly Diagnosed ◽  
Poor Prognostic Factor ◽  
Plasma Cell Dyscrasias

Using fluorescence in situ hybridization we investigated amplification of chromosome band 1q21 (Amp1q21) in more than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS; n = 14), smoldering multiple myeloma (SMM; n = 31), and newly diagnosed MM (n = 479) as well as 45 with relapsed MM. The frequency of Amp1q21 was 0% in MGUS, 45% in SMM, 43% in newly diagnosed MM, and 72% in relapsed MM (newly diagnosed versus relapsed MM, P < .001). Amp1q21 was detected in 10 of 12 patients whose disease evolved to active MM compared with 4 of 19 who remained with SMM (P < .001). Patients with newly diagnosed MM with Amp1q21 had inferior 5-year event-free/overall survival compared with those lacking Amp1q21 (38%/52% versus 62%/78%, both P < .001). Thalidomide improved 5-year EFS in patients lacking Amp1q21 but not in those with Amp1q21 (P = .004). Multivariate analysis including other major predictors revealed that Amp1q21 was an independent poor prognostic factor. Relapsed patients who had Amp1q21 at relapse had inferior 5-year postrelapse survival compared with those lacking Amp1q21 at relapse (15% versus 53%, P = .027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis.

scholarly journals Increased Expression Of SOX2 Predicts A Poor Prognosis And Promotes Malignant Phenotypes In Upper Tract Urothelial Carcinoma

2019 ◽  
Vol Volume 11 ◽  
pp. 9095-9106 ◽  
Author(s):  
Zhengqing Bao ◽  
Yonghao Zhan ◽  
Shiming He ◽  
Yifan Li ◽  
Bao Guan ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Poor Prognosis ◽  
Upper Tract Urothelial Carcinoma ◽  
Upper Tract

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

1997 ◽  
Vol 15 (8) ◽  
pp. 2894-2904 ◽  
Author(s):  
M F Press ◽  
L Bernstein ◽  
P A Thomas ◽  
L F Meisner ◽  
J Y Zhou ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Gene Amplification ◽  
Poor Prognosis ◽  
Southern Hybridization ◽  
Recurrent Disease ◽  
Breast Cancers ◽  
Node Negative ◽  
Her 2

PURPOSE The HER-2/neu gene codes for a membrane receptor protein that is homologous, but distinct from the epidermal growth factor receptor. This investigation was performed to validate fluorescence in situ hybridization (FISH) as a sensitive and specific method for assessing HER-2/neu gene amplification in archival tissue and to test whether this alteration is associated with poor prognosis. MATERIALS AND METHODS HER-2/neu gene amplification was determined by FISH in 140 archival breast cancers, previously characterized for gene amplification by Southern hybridization or dot-blot hybridization, and for gene expression by Northern hybridization, Western immunoblot, or immunohistochemistry. A separate cohort of 324 node-negative breast cancers was assessed for amplification by FISH to determine the utility of HER-2/neu gene amplification. RESULTS Relative to solid-matrix blotting procedures, FISH analysis of HER-2/neu gene amplification showed a sensitivity of 98% and a specificity of 100% in 140 breast cancers. Among patients treated by surgery only, the relative risks (relative hazard) of early recurrence (recurrent disease within 24 months of diagnosis), recurrent disease (at any time), and disease-related death were statistically significantly associated with amplification. The prognostic information contributed by HER-2/neu amplification was independent of the other markers studied. CONCLUSION FISH was an alternative technique for determining gene amplification and had some distinct advantages over Southern hybridization. Our results demonstrate that HER-2/neu gene amplification in the absence of adjuvant therapy is an independent predictor of poor clinical outcome and is a stronger discriminant than tumor size. Women with small tumors that had gene amplification were at increased risk of recurrence and disease-related death.

Sign in / Sign up

Export Citation Format

Share Document